Your browser doesn't support javascript.
loading
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Supasa, Piyada; Zhou, Daming; Dejnirattisai, Wanwisa; Liu, Chang; Mentzer, Alexander J; Ginn, Helen M; Zhao, Yuguang; Duyvesteyn, Helen M E; Nutalai, Rungtiwa; Tuekprakhon, Aekkachai; Wang, Beibei; Paesen, Guido C; Slon-Campos, Jose; López-Camacho, César; Hallis, Bassam; Coombes, Naomi; Bewley, Kevin R; Charlton, Sue; Walter, Thomas S; Barnes, Eleanor; Dunachie, Susanna J; Skelly, Donal; Lumley, Sheila F; Baker, Natalie; Shaik, Imam; Humphries, Holly E; Godwin, Kerry; Gent, Nick; Sienkiewicz, Alex; Dold, Christina; Levin, Robert; Dong, Tao; Pollard, Andrew J; Knight, Julian C; Klenerman, Paul; Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij-Rammerstorfer, Sandra; Gilbert, Sarah; Hall, David R; Williams, Mark A; Paterson, Neil G; James, William; Carroll, Miles W; Fry, Elizabeth E; Mongkolsapaya, Juthathip.
Afiliação
  • Supasa P; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Zhou D; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Liu C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Mentzer AJ; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Ginn HM; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Zhao Y; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Duyvesteyn HME; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Nutalai R; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Tuekprakhon A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wang B; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Paesen GC; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Slon-Campos J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • López-Camacho C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hallis B; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Coombes N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Bewley KR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Charlton S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Walter TS; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Barnes E; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Dunachie SJ; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
  • Skelly D; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Lumley SF; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Baker N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Shaik I; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Humphries HE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Godwin K; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Gent N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Sienkiewicz A; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Dold C; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Levin R; Worthing Hospital, Worthing, UK.
  • Dong T; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Ox
  • Pollard AJ; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Knight JC; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Klenerman P; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Crook D; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Lambe T; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Clutterbuck E; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Bibi S; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Flaxman A; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bittaye M; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Belij-Rammerstorfer S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Gilbert S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hall DR; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Williams MA; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Paterson NG; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • James W; Sir William Dunn School of Pathology University of Oxford, Oxford, UK.
  • Carroll MW; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Fry EE; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Mongkolsapaya J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Researc
Cell ; 184(8): 2201-2211.e7, 2021 04 15.
Article em En | MEDLINE | ID: mdl-33743891
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / COVID-19 / Anticorpos Monoclonais / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / COVID-19 / Anticorpos Monoclonais / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2021 Tipo de documento: Article